Surgical management of duodenal ulcer.

R. Colp

1950-09-01

Abstract:

What problem does this paper attempt to address?

Validation of the pathological prognostic staging system proposed in the revised eighth edition of the AJCC staging manual in different molecular subtypes of breast cancer

Nuri Jang,Jung Eun Choi,Su Hwan Kang,Young Kyung Bae

DOI: https://doi.org/10.1007/s00428-018-2495-x

Abstract:The authors investigated the clinical utility of the revised prognostic staging system proposed in the eighth edition of the American Joint Committee on Cancer (AJCC) staging manual in breast cancer (BC) patients. We retrospectively reviewed the data of 714 BC patients that received surgical treatment and standard adjuvant therapy from January 2005 to December 2007. All patients were restaged for anatomic TNM stage and pathological prognostic (PP) stage as defined in the revised eighth edition of the AJCC manual. Compared with anatomic stage, PP stage was different from anatomic stage in 325 (45.5%) patients, 254 were down-staged and 71 were upstaged. There were significant differences in overall survival (OS) and disease-free survival (DFS) according to different anatomic stages or PP stages (all, p < 0.001). In anatomic stage I patients, OS was significantly different between PP stages IA and IB (p < 0.001), but no significant difference was observed between anatomic stages IA and IB (p = 0.413). PP stages exhibited significant OS differences in anatomic stage IIB (p = 0.011), but survival differences according to PP stages were not observed in anatomic stage IIA, IIIA, or IIIC. PP stages were found to have prognostic value with respect to OS and DFS for luminal (p < 0.001 and p < 0.001), HER2-positive (p = 0.001 and p = 0.013), and triple-negative (p = 0.008 and p = 0.03) subtypes. The prognostic staging system proposed in the eighth edition of the AJCC more accurately predicts the clinical outcomes of BC patients than the traditional anatomic staging system.
A prospective observational study on the accuracy of patient self‐testing of urine at an antenatal clinic

J. Goh,H. Krause

DOI: https://doi.org/10.1111/j.0004-8666.2002.00073.x

2002-02-01

Australian and New Zealand Journal of Obstetrics and Gynaecology

Abstract:This study was performed to assess whether assigning dipstick self‐testing of urine to antenatal women maintained accuracy and clinical relevance of the results. A total of 212 women were recruited from the routine antenatal clinic for the assessment of accuracy of self‐testing of urine. The women's results were compared to that of the one nurse who routinely performs dipstick testing at the antenatal clinic.
Prognostic Stage Groups Established by AJCC Staging System 8th Edition Does Not Significantly Improve Discrimination over Classic TNM Staging in Early Stage Breast Cancer Treated with Breast Conservative Therapy

S. Chen,S. Wang,Y. Tang,Z. H. Yu,J. Jin,Y. P. Liu,X. F. Liu,Y. W. Song,H. Fang,Y. Li

DOI: https://doi.org/10.1016/j.ijrobp.2017.06.607

2017-01-01

Abstract:The new AJCC staging system 8th edition established the prognostic stage groups for breast cancer, which incorporates biomarkers into classic TNM system to improve discrimination over anatomic stage group. This study is to verify whether AJCC Stage staging system 8th edition is superior to 7thin early stage breast treated with breast conservative therapy, and help to individualize their treatment. 1602 patients with T1-2N0-1M0 breast cancer treated from 1999 to 2013 were retrospectively reviewed. All underwent breast conserving surgery plus axillary lymph node dissection or sentinel node biopsy without neoadjuvant chemotherapy. 1220 patients who had complete information on histological grade, ER, PR and Her2 status were included in this analysis. The median age was 46 years (range, 20-84). 1054 (86.4%) received radiotherapy, 900 (73.8%) received hormone therapy, and 91 (7.5%) received trastuzumab targeted therapy. All patients were restaged according to the new AJCC staging system 8thedition. Locoregional recurrence (LRR), disease free survival (DFS) and overall survival (OS) were calculated by using the Kaplan-Meier method and compared by log-rank test. With a median follow-up of 47 months (IQR, 34-74months), the overall 5-year LRR was 3.6%, 5-year DFS was 93.4%,and 5-year OS was 99.2%. By AJCC 7th staging system, 803 (65.8%) patients had stage IA and 417 (34.2%) had stage IIA diseases. Patients with stage IIA had significant lower DFS than stage IA, but there were no significant difference in OS and LRR between the two groups (Table 1). By AJCC 8th staging system, 608 (49.8%) patients were assigned to a different group, with 250 (41.1%) to a lower stage and 358 (58.9%) to a higher stage. AJCC 8th staging system can help identify a group of patients such as IIIA with significant worse LRR and DFS, but didn’t improve discrimination on OS as compared with AJCC 7th staging system ( Table 1 ). For early stage breast cancer treated with breast conservative therapy, AJCC 8th staging system doesn’t significantly improve discrimination over classic TNM staging. It might need further investigation on prognostic biomarkers.Abstract 2016; Table 1Five-Year Outcomes According to Different Stage GroupsNo. (%)5year-LRR (%)5year-DFS (%)5year-OS (%)Stage7th8th7th8th7th8th7th8thIA803 (65.8)554 (45.4)2.62.194.796.099.199.6IB395 (32.4)4.191.298.8IIA417 (34.2)162 (13.3)5.33.190.894.099.498.8IIB54 (4.4)4.093.097.4IIIA55 (3.4)15.681.593.8P value0.118<0.0010.016<0.0010.5730.291 Open table in a new tab
Validation of the Prognostic Significance of the Prognostic Stage Group According to the Eighth Edition of American Cancer Joint Committee on Cancer Staging System in Triple-Negative Breast Cancer: An Analysis From Surveillance, Epidemiology, and End Results 18 Database

Shi-Ping Luo,Qi-Sen Wu,Hong Chen,Xiao-Xiao Wang,Qing-Xia Chen,Jie Zhang,Chuan-Gui Song

DOI: https://doi.org/10.1016/j.jss.2019.09.072

Abstract:Background: The eighth edition of the American Cancer Joint Committee on Cancer (AJCC) staging system for breast cancer put forward the prognostic stage groups for the first time based on the traditional anatomic tumor-node-metastasis staging system. Our study intends to validate the predictive significance of the eighth edition staging system in triple-negative breast cancer (TNBC) patients. Materials and methods: We collected and accessed 26,589 eligible cases of TNBC from the Surveillance, Epidemiology, and End Results database (2010-2015) and reclassified the patient cohort according to the eighth edition of the AJCC staging system into anatomic and prognostic stages. Results: The results showed that more than half of the patients upstaged in the prognostic stage when compared with the anatomic stage. By comparing with the anatomic stage, the prognostic stage had a higher likelihood ratio and linear trend χ2 values. The prognostic stage group also had higher Akaike information criterion and Bayesian information criterion values than the anatomic stage group. Conclusions: The prognostic staging system in TNBC patients performs more optimistic prognostic stratification and predictability than the anatomic staging system. Moreover, the latest AJCC staging system has a milestone importance to the history of breast cancer staging system.
Metal chelators coupled with nanoparticles as potential therapeutic agents for Alzheimer's disease.

Gang Liu,P. Men,George Perry,Mark A. Smith

DOI: https://doi.org/10.1166/JNS.2009.005

2009-06-01

Journal of Nanoneuroscience

Abstract:Alzheimer's disease (AD) is a devastating neuro-degenerative disorder characterized by the progressive and irreversible loss of memory followed by complete dementia. Despite the disease's high prevalence and great economic and social burden, an explicative etiology or viable cure is not available. Great effort has been made to better understand the disease's pathogenesis, and to develop more effective therapeutic agents. However, success is greatly hampered by the presence of the blood-brain barrier that limits a large number of potential therapeutics from entering the brain. Nanoparticle-mediated drug delivery is one of the few valuable tools for overcoming this impediment and its application as a potential AD treatment shows promise. In this review, the current studies on nanoparticle delivery of chelation agents as possible therapeutics for AD are discussed because several metals are found excessive in the AD brain and may play a role in the disease development. Specifically, a novel approach involving transport of iron chelation agents into and out of the brain by nanoparticles is highlighted. This approach may provide a safer and more effective means of simultaneously reducing several toxic metals in the AD brain. It may also provide insights into the mechanisms of AD pathophysiology, and prove useful in treating other iron-associated neurodegenerative diseases such as Friedreich's ataxia, Parkinson's disease, Huntington's disease and Hallervorden-Spatz Syndrome. It is important to note that the use of nanoparticle-mediated transport to facilitate toxicant excretion from diseased sites in the body may advance nanoparticle technology, which is currently focused on targeted drug delivery for disease prevention and treatment. The application of nanoparticle-mediated drug transport in the treatment of AD is at its very early stages of development and, therefore, more studies are warranted.
Comparison of the 7th and 8th edition of American Joint Committee on Cancer (AJCC) staging systems for breast cancer patients: a Surveillance, Epidemiology and End Results (SEER) Analysis.

Nan Shao,Chuanbo Xie,Yawei Shi,Runyi Ye,Jianting Long,Huijuan Shi,Zhen Shan,Alastair M Thompson,Ying Lin

DOI: https://doi.org/10.2147/CMAR.S185212

2019-01-01

Cancer Management and Research

Abstract:Background: The 8th edition of the American Joint Committee on Cancer (AJCC) staging system for breast cancer has incorporated tumor grade, estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status as staging biologic factors reflecting prognosis. The purpose of this study was to compare the 7th and 8th edition of AJCC staging system for prognostic impact. Materials and methods: Primary breast cancer patients diagnosed from 2010 to 2014 were identified using the Surveillance, Epidemiology and End Results 18 registries research database. Breast cancer-specific survival (BCSS) and overall survival (OS) between stages were estimated using the Kaplan-Meier method and compared using the log-rank test. Multivariable analysis was performed using Cox proportional hazards regression analysis to identify factors independently associated with outcome. Akaike's information criterion (AIC) was calculated to estimate how well the staging system fitted the data and the complexity of the model. Results: A total of 184,221 primary breast cancer patients were identified in the 7th AJCC staging system; 16,145 (8.8%) patients could not be categorized according to 8th AJCC prognostic staging system leaving 168,076 patients included for final analyses. The 8th AJCC performed well with the BCSS and OS concordant with stage. A total of 89,494 (53.2%) of patients were restaged to a different stage group in the 8th AJCC; stage IIIA in the 7th AJCC migrated to stage IB with a worse prognosis than IIA and IIB in the 8th AJCC. Nevertheless, the 8th AJCC had a better AIC than the 7th staging system. Conclusion: The prognostic accuracy of the 8th AJCC staging system was generally superior to the 7th AJCC, although subtle differences between the two systems should be noted in comparative studies.
Validation of the American Joint Committee on Cancer (AJCC) 8th edition stage system for gastric cancer patients: a population-based analysis

Xingkang He,Wenrui Wu,Zhenghua Lin,Yue Ding,Jianmin Si,Lei-min Sun

DOI: https://doi.org/10.1007/s10120-017-0770-1

2017-01-01

Abstract:Background Our aim was to validate the American Joint Committee on Cancer (AJCC) 8th edition stage system for gastric cancer in the Western world and to compare several modifications between the 7th and 8th edition systems. Methods Eligible patients having undergone surgical resection of gastric cancer during 2004–2011 from the Surveillance, Epidemiology, and End Results (SEER) database were included in the current study. Survival differences were assessed by Kaplan–Meier curve and log-rank tests. The discriminative power of the AJCC 8th and 7th editions was compared by Harrell’s concordance index (c-index). Results Patients with pN3a and pN3b presented distinct survival outcomes, especially for cases in which more than 15 lymph nodes were examined. The overall (OS) and cancer-specific survival (CSS) c-indices for the 8th edition were largely comparable with c-indices for the 7th edition throughout the cohort. Notably, the new edition improved the power of discrimination slightly in OS and CSS (c-indices: 0.717, 0.744) compared with the 7th edition (c-indices: 0.712, 0.739) for patients for whom 15 or more lymph nodes were examined. The analysis of stage migration in the new edition revealed nonhomogeneous survival outcomes in stages IIIB and IIIC. Conclusion The AJCC 8th stage system for gastric cancer performs as well as the AJCC 7th edition in the United States (USA). Importantly, when more than 15 lymph nodes are examined, the discriminatory performance of the new edition is improved.
Organochlorine pesticides associated with ocular, nasal, or otic infection in the eastern box turtle (Terrapene carolina carolina).

B. Tangredi,R. Evans

Journal of Zoo and Wildlife Medicine

Abstract:From May 1987 to September 1994, 19 eastern box turtles (Terrapene carolina carolina) originating from scattered locations on Long Island, New York (USA) were presented with one or more of the following signs: listlessness, ocular and nasal discharge, conjunctivitis, blepharitis, and otitis media. Numerous species of bacteria and yeast were isolated by aerobic culture. Histopathologic findings confirmed chronic active bacterial infections. Toxicologic analyses of livers revealed elevated concentrations of chlordane metabolites in two diseased turtles. A third turtle liver contained residues of endosulfan sulfate. Immunosuppressive effects of low-level exposure to organochlorines, including chlordane and endosulfan, could be involved in the pathogenesis of the observed infections.
Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual

Armando E Giuliano,James L Connolly,Stephen B Edge,Elizabeth A Mittendorf,Hope S Rugo,Lawrence J Solin,Donald L Weaver,David J Winchester,Gabriel N Hortobagyi

DOI: https://doi.org/10.3322/caac.21393

2017-07-08

Abstract:Answer questions and earn CME/CNE The revision of the eighth edition of the primary tumor, lymph node, and metastasis (TNM) classification of the American Joint Commission of Cancer (AJCC) for breast cancer was determined by a multidisciplinary team of breast cancer experts. The panel recognized the need to incorporate biologic factors, such as tumor grade, proliferation rate, estrogen and progesterone receptor expression, human epidermal growth factor 2 (HER2) expression, and gene expression prognostic panels into the staging system. AJCC levels of evidence and guidelines for all tumor types were followed as much as possible. The panel felt that, to maintain worldwide value, the tumor staging system should remain based on TNM anatomic factors. However, the recognition of the prognostic influence of grade, hormone receptor expression, and HER2 amplification mandated their inclusion into the staging system. The value of commercially available, gene-based assays was acknowledged and prognostic input added. Tumor biomarkers and low Oncotype DX recurrence scores can alter prognosis and stage. These updates are expected to provide additional precision and flexibility to the staging system and were based on the extent of published information and analysis of large, as yet unpublished databases. The eighth edition of the AJCC TNM staging system, thus, provides a flexible platform for prognostic classification based on traditional anatomic factors, which can be modified and enhanced using patient biomarkers and multifactorial prognostic panel data. The eighth edition remains the worldwide basis for breast cancer staging and will incorporate future online updates to remain timely and relevant. CA Cancer J Clin 2017;67:290-303. © 2017 American Cancer Society.
Pharmacokinetics of an antiallergic agent, 1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-1H-1, 4-diazepin-1-yl)-1H-benzimidazole difumarate (KG-2413) after oral administration: interspecies differences in rats, guinea pigs and dogs.

T. Sakai,T. Hamada,N. Awata,J. Watanabe

DOI: https://doi.org/10.1248/BPB1978.12.530

1989-09-01

Journal of Pharmacobio-Dynamics

Abstract:The pharmacokinetics of an antiallergic agent, 1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-1H-1, 4-diazepin-1-yl)-1H-benzimidazole difumarate (KG-2413) after oral administration were studied in rats, guinea pigs and dogs. Maximum plasma level (Cmax) appeared at 23, 32 and 51 min after dosing in rats, guinea pigs and dogs, respectively. Plasma half-lives of the terminal phase were comparable to those after intravenous administration in each animal species. Pronounced interspecies differences were observed in the Cmax/dose and area under the plasma concentration-time curve (AUC)/dose, namely, these values were high in guinea pigs and low in rats and dogs. The extents of bioavailability were 0.036 in rats (20 mg/kg), 0.50 in guinea pigs (2 mg/kg) and 0.052 in dogs (2 mg/kg). These variations in the pharmacokinetic parameters in the animals were assumed to be mostly due to the species difference in the hepatic intrinsic clearance.
Validation of the Postneoadjuvant Therapy Pathological Stage of the American Joint Committee on Cancer (AJCC) 8th Edition for Predicting Outcomes of Esophageal Squamous Cell Carcinoma (ESCC) Patients Receiving Neoadjuvant Chemoradiotherapy (CRT) Followed by Esophagectomy.

Tsung-hao Liu,Hung-Yang Kuo,Jhe-Cyuan Guo,Chia-Chi Lin,Ta-Chen Huang,Min-Shu Hsieh,Jang-Ming Lee,Chih-Hung Hsu

DOI: https://doi.org/10.1200/jco.2018.36.4_suppl.138

IF: 45.3

2018-01-01

Journal of Clinical Oncology

Abstract:138 Background: The AJCC 8th edition staging system introduces a new postneoadjuvant therapy staging category (ypTNM-8th) for ESCC patients receiving neoadjuvant treatment followed by esophagectomy. Whether this new staging category has better prognostic prediction than the pathological staging category of AJCC 7th edition (ypTNM-7th) needs validation. Methods: We enrolled ESCC patients receiving neoadjuvant paclitaxel/cisplatin-based CRT (RT = 40Gy) followed by esophagectomy from three phase II trials conducted in the National Taiwan University Hospital. The prognostic prediction abilities of the ypTNM-8th and the ypTNM-7th on patients’ survivals were compared using Cox regression, concordance index (C-index), R-square, and Akaike information criteria (AIC). Results: A total 135 patients (M:F = 127: 8, median age:53.0 years) were enrolled. With a median follow-up of 31.3 months, the median PFS and OS of all patients were 24.4 months (95% CI: 15.4-33.5) and 33.9 months (95% CI: 22.6-45.1), respectively. In univariate analysis, both ypTNM-8th and ypTNM-7th had statistically significant prognostic effects for PFS and OS. In multivariate analysis on OS, the ypTNM-8th demonstrated a statistically significant predicting effect (P = 0.015) while the ypTNM-7th did not (P = 0.051). Although there is no statistically different between ypTNM-8th and ypTNM-7th by R-square analysis, the ypTNM-8th had lower AIC and C-index for both PFS and OS, meaning an better efficiency of predicting survivals, than ypTNM-7th. Conclusions: The new ypTNM-8th may have better prognostic prediction for OS of locally advanced ESCC patients receiving neoadjuvant CRT than the ypTNM-7th. (Granted by 106-HCH029)
The Effect of the New Eighth Edition Breast Cancer Staging System on 100 Consecutive Patients

Ashley Biswal,Jacqueline Erler,Omar Qari,Arthur A Topilow,Varsha Gupta,Mohammad A Hossain,Arif Asif,Brian Erler,Denise Johnson Miller

DOI: https://doi.org/10.14740/jocmr3803

Abstract:Background: In October 2016 the American Joint Committee on Cancer published the early eighth edition breast cancer prognostic staging system, incorporating biomarkers into previously accepted staging. The updated and current eighth edition became effective nationwide in January 2018 after a large update to its staging guidelines. This study's aim was to compare patients' anatomic seventh edition (anatomic), early eighth (pre-update, prognostic), and current eighth (post-update, prognostic) pathological stages and to assess the utility of recent inclusions to staging criteria. Additionally, we observed how the aforementioned stage changes aligned with breast cancer histologic subtypes. Methods: An Institutional Review Board (IRB)-approved retrospective chart review was performed. Inclusion criteria included female patients between the ages of 35 to 95 years with a diagnosis of invasive ductal or lobular carcinoma of the breast (n = 100) at three Hackensack Meridian Health hospitals. The study evaluated any trends in patients' stage changes between the seventh edition, early eighth edition, and current eighth edition breast cancer staging guidelines. Breast cancer restaging was performed using a novel staging tool on Microsoft Excel. Results: Only 26% of patients' stages changed when comparing the seventh edition stage vs. current eighth edition prognostic staging, most of which were downstaged. When comparing the seventh with early eighth edition prognostic staging, 38% of the patients' stages changed, with a majority of them being upstaged. Lastly, 95% of total stage changes were downstages between the early eighth and current eighth edition staging guidelines. Conclusions: When comparing the seventh edition vs. current eighth edition staging, few patients (especially those with early stage cancer) underwent a stage change. However, there were significant changes in stage when comparing early eighth vs. current eighth stages. Considering these changes were mostly downstages and many patients reverted to their original seventh edition stage, the current eighth edition is based on a personalized, less radical staging approach, one that is more synonymous with original seventh edition staging.
Best-Worst Scaling: A simple method to determine drinks and wine style preferences

Steve Goodman,L. Lockshin,Eli Cohen

Abstract:Wine marketers are continually involved with measuring consumer preferences usually by means of surveys or consumer purchase panel data. In this paper we provide initial results using a relatively new and very straightforward method for measuring consumer preferences. The best-worst scaling method (also called max-diffs) simply asks consumers to look at sets of products, attributes, or other factors to be compared and choose from each set the best/most favourable and the worst/least favourable. A simple count and manipulation results in a single preference scale, where the differences may be compared as distances rather than rank order. Managerial implications of the importance of wine attributes that influence consumer drinks purchasing and wine style selection are discussed as well as suggestions for future research. The goal of this paper is to demonstrate the practical and a scholarly usefulness of this approach and present a call for replication in other markets in an ongoing manner.
クロラムフェニコール, チアムフェニコール及びペニシリンによる老年者急性骨髄機能不全に関する血液学的検討, とくに末梢血液像および肝機能について

T. Shirakura,Y. Murai,M. Kobayashi

DOI: https://doi.org/10.3143/GERIATRICS.14.460

1977-11-30

Abstract:Chloramphenicol (CP), thiamphenicol (TP), aminobenzylpenicillin, carbenicillin (AB-Pc, CB-Pc) による老年者の急性造血障害例17例について, 原因薬剤の投与条件や末梢血液像につき検討するとともに, CP, TP例については, とくにこれら薬剤による造血障害発現に関与する肝, 腎機能について造血障害非発現例と比較検討した. えられた成積は次の如くであった.1. 原因薬剤はCP, TP 13例, AB-Pc 3例, CB-Pc 1例で, TP例が圧倒的に多かったが, 障害血液細胞は赤血球系が17例中15例と最も多く, ついで血小板系障害の頻度が多かった. 死亡したCP, AB-Pc各1例以外の症例は, 他の原因で死亡した1例を除いて, 原因薬剤投与を中止後, 障害細胞の速やかな回復がみられた.2. CP, TP投与例中, 造血障害を発現した例と発現しなかった例とについて, 原因薬剤投与時の対象の肝, 腎機能検査成積を比較検討した. その結果, GPT異常高値が, CP, TP造血障害例に有意に多いことが示された.3. TP 2例, AB-Pc 1例では, 造血障害とともに肝機能障害が同時にみとめられた. 時間的経過からみて, 両障害は原因薬剤により別個に惹起されたと解された.老年者においては, 上記薬剤とくにCP, TPでは, 急性造血障害を惹起する頻度が, 一般にいわれている発現率に比して高い成積をえた.しかしこれら造血障害例の大部分は, 原因薬剤の投与を中止することにより, 多くは2乃至7日の間に障害血液細胞の急速な回復をみた. また肝障害をもつ老年者でのCP, TP造血障害発現が有意に高いことが指摘された点からみて, これら薬剤の使用に際しては, 投与対象例について, この点に留意するとともに, 薬剤使用中には末梢血液中の網赤血球を含む血液像の変化に注意し, 異常あれば速やかに投与を中止すれば, 薬剤による急性造血障害を最小限に防止しうることが指摘された.
The Predictive Value of the Prognostic Staging System in the 8th Edition of the American Joint Committee on Cancer for Triple-Negative Breast Cancer: a SEER Population-Based Analysis

Ying-Ying Liu,Tian-Jian Yu,Guang-Yu Liu

DOI: https://doi.org/10.2217/fon-2018-0145

2019-01-01

Future Oncology

Abstract:Aim: To examine the stage changes and survival differences among triple-negative breast cancer (TNBC) patients based on the prognostic staging system. Methods: We used the SEER database to identify eligible patients with TNBC diagnosed between 2010 and 2014. Kaplan-Meier curves were drawn for comparison. The primary end point was breast cancer-specific survival. Results: The median follow-up time was 26 months for 19,608 patients. The stages of all TNBC patients increased or remained unchanged during rearrangement from anatomic staging to prognostic staging. Stage IIA, IIIA and IIIC comprised the majority of patients. Several patients did not have prognostic staging. Stage IIIC incorporated six substages that contributed to high heterogeneity. Overall, the Kaplan-Meier curves still showed the favorable differentiation among stages and substages, with the exception of stage IIB and substage IIIA (T2N0, grade 2-3) patients. Conclusion: The prognostic information for breast cancer patients provided by the novel prognostic staging system may be less accurate for TNBC patients in our independent analysis. Moreover, stage IIB and substage IIIA (T2N0, grade 2-3) should possibly undergo further evaluation.
A Retrospective Survival Analysis of Anatomic and Prognostic Stage Group Based on the American Joint Committee on Cancer 8th Edition Cancer Staging Manual in Luminal B Human Epidermal Growth Factor Receptor 2-negative Breast Cancer.

Ling Xu,Jiang-Hong Li,Jing-Ming Ye,Xue-Ning Duan,Yuan-Jia Cheng,Ling Xin,Qian Liu,Bin Zhou,Yin-Hua Liu

DOI: https://doi.org/10.4103/0366-6999.211896

IF: 6.133

2017-01-01

Chinese Medical Journal

Abstract:BACKGROUND:Current understanding of tumor biology suggests that breast cancer is a group of diseases with different intrinsic molecular subtypes. Anatomic staging system alone is insufficient to provide future outcome information. The American Joint Committee on Cancer (AJCC) expert panel updated the 8th edition of the staging manual with prognostic stage groups by incorporating biomarkers into the anatomic stage groups. In this study, we retrospectively analyzed the data from our center in China using the anatomic and prognostic staging system based on the AJCC 8th edition staging manual. METHODS:We reviewed the data from January 2008 to December 2014 for cases with Luminal B Human Epidermal Growth Factor Receptor 2 (HER2)-negative breast cancer in our center. All cases were restaged using the AJCC 8th edition anatomic and prognostic staging system. The Kaplan-Meier method and log-rank test were used to compare the survival differences between different subgroups. SPSS software version 19.0 (IBM Corp., Armonk, NY, USA) was used for the statistical analyses. RESULTS:This study consisted of 796 patients with Luminal B HER-negative breast cancer. The 5-year disease-free survival (DFS) of 769 Stage I-III patients was 89.7%, and the 5-year overall survival (OS) of all 796 patients was 91.7%. Both 5-year DFS and 5-year OS were significantly different in the different anatomic and prognostic stage groups. There were 372 cases (46.7%) assigned to a different group. The prognostic Stage II and III patients restaged from anatomic Stage III had significant differences in 5-year DFS (χ2 = 11.319, P= 0.001) and 5-year OS (χ2 = 5.225, P= 0.022). In addition, cases restaged as prognostic Stage I, II, or III from the anatomic Stage II group had statistically significant differences in 5-year DFS (χ2 = 6.510, P= 0.039) but no significant differences in 5-year OS (χ2 = 5.087, P= 0.079). However, the restaged prognostic Stage I and II cases from anatomic Stage I had no statistically significant differences in either 5-year DFS (χ2 = 0.440, P= 0.507) or 5-year OS (χ2 = 1.530, P= 0.216). CONCLUSIONS:The prognostic staging system proposed in the AJCC 8th edition refines the anatomic stage group in Luminal B HER2-negative breast cancer and will lead to a more personalized approach to breast cancer treatment.
The Prognostic Value of the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging System in HER2-Enriched Subtype Breast Cancer, a Retrospective Analysis.

Bin Zhou,Ling Xu,Jingming Ye,Ling Xin,Xuening Duan,Yinhua Liu

DOI: https://doi.org/10.21873/anticanres.11862

2017-01-01

Anticancer Research

Abstract:Background/Aim: The American Joint Committee on Cancer (AJCC) released its 8th edition of tumor staging which is to be implemented in early 2018. The present study aimed to analyze the prognostic value of AJCC 8th edition Cancer Staging System in HER2-enriched breast cancer, on a retrospective cohort. Patients and Methods: This study was a retrospective single-center study of HER2-enriched breast cancer cases diagnosed from January 2008 to December 2014. Clinicopathological features and follow up data including disease-free survival (DFS) and overall survival (OS) were analyzed to explore prognostic factors for disease outcome. We restaged patients based on the 8th edition of the AJCC cancer staging system and analyzed prognostic value of the Anatomic Stage Group and the Prognostic Stage Group. Results: The study enrolled 170 HER2-enriched subtype breast cancer patients with 5-year disease free survival (DFS) of 85.1% and 5-year overall survival (OS) of 86.8%. Prognostic stages of 117 cases (68.8%) changed compared with anatomic stages, with 116 upstaged cases and 1 downstaged case. The Anatomic Stage Groups had a significant prognostic impact on DFS (chi(2)=16.752, p<0.001) and OS (chi(2)=25.038, p<0.001). The Prognostic Staging Groups had a significant prognostic impact on DFS (chi(2)=6.577, p=0.037) and OS (chi(2)=21.762, p<0.001). In the multivariate analysis, both stage groups were independent predictors of OS. Conclusion: Both Anatomic and Prognostic Stage Groups in the 8th edition of the AJCC breast cancer staging system had prognostic value in HER2-enriched subtype breast cancer. The Prognostic Stage system was a breakthrough on the basis of anatomic staging system.
Abstract PO5-27-01: Comparison between the 7th and the 8th edition of TNM Staging System of American joint committee on Cancer(AJCC) for Breast Cancer Patients, diagnosed and treated at King Abdulaziz Medical City

Nafisa Abdelhafiez,Abdulmohsen Alkushi,Lolwah Alriyees,Mohammad Arabi,Faris Alsalamah,Emad Masuadi,Ahmad Omair,Mohammad Alkaiyat,Hussam Shehata

DOI: https://doi.org/10.1158/1538-7445.sabcs23-po5-27-01

IF: 11.2

2024-05-03

Cancer Research

Abstract:Breast cancer is a heterogeneous disease with different biological and molecular characteristics that affect local recurrence, metastases, prognoses, and response to available therapies. The 8th edition of the American Joint Committee on Cancer (AJCC) staging system for breast cancer has incorporated the biological and molecular characteristics, tumor grade, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor status(Her-2)and tumor grade, into the traditional anatomical 7th edition that only considers tumor size, lymph nodes status, and distant metastases. The aim of this study is to compare the 7th to 8th editions of the AJCC staging system for prognostic impact, assess the effect of the new edition on the treatment and treatment outcome Method A retrospective cohort study was performed for all breast cancer patients, diagnosed between (2013 -2019) and underwent upfront surgery at King Abdulaziz Medical City (KAMC).Patients' clinicopathological, immunohistochemical, surgical, therapeutic, and follow-up data were retrieved. Overall survival (OS) and breast cancer-specific survival (BCSS) were estimated using the Kaplan–Meier method. Univariate analysis using Fisher's exact test was used to compare staging systems' prognostic accuracy. Multivariable analysis using Cox proportional hazards regression analysis was performed to identify factors independently associated with disease outcome Results A total of 169 female patients were included, the 8th AJCC staging system resulted in a reallocation of 108 (63.9%) of the patients to a different stage group. The majority were downstaged(60.9%) while only 3% were upstaged, most of the upstaged patients had a triple-negative subtype (80%). The change in overall stage for the 8th edition was most significant in stage I (an increase by 140.3%), followed by stage II (downstaged by 74.3%) and stage III (downstaged by 49.7%) compared to the 7th edition. Critically 42.8% of all downstaged patients treated with adjuvant chemotherapy were found to have received unnecessary chemotherapy after applying the 8th AJCC staging system as per National Comprehensive Cancer Network (NCCN) clinical practice guidelines recommendations. The 8th AJCC staging system was a better prognostic predictor of disease survival, patients in 8th AJCC stage 3 had a higher tendency to develop metastases and die because of their disease (P-value 0.03, 0.051, respectively). Conclusions: Our comparison revealed that the AJCC 8th edition staging system is superior and more comprehensive than the 7th, in term of prognostic value, and in defining the precise adjuvant therapy Figure 1 Comparison of the 7th AJCC and the 8th AJCC staging system Citation Format: Nafisa Abdelhafiez, Abdulmohsen Alkushi, Lolwah Alriyees, Mohammad Arabi, Faris Alsalamah, Emad Masuadi, Ahmad Omair, Mohammad Alkaiyat, Hussam Shehata. Comparison between the 7th and the 8th edition of TNM Staging System of American joint committee on Cancer(AJCC) for Breast Cancer Patients, diagnosed and treated at King Abdulaziz Medical City [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl) nr PO5-27-01.

oncology
Prognostic and Predictive Value of the American Joint Committee on Cancer Pathological Prognostic Staging System in Nodal Micrometastatic Breast Cancer

Jian Shi,Chen-Lu Lian,Feng Chi,Ping Zhou,Jian Lei,Li Hua,Jun Wang,Zhen-Yu He,San-Gang Wu

DOI: https://doi.org/10.3389/fonc.2020.570175

IF: 4.7

2020-12-18

Frontiers in Oncology

Abstract:Introduction To investigate the prognostic and predictive effect of the American Joint Committee on Cancer (AJCC) 8 th edition pathological prognostic staging system in patients with T1-2N1micM0 breast cancer who underwent mastectomy. Methods Data from T1-2N1micM0 breast cancer patients who underwent mastectomy from 2010–2014 were obtained from the Surveillance, Epidemiology, and End Results program. The chi-square test, binomial logistics regression, receiver-operating characteristics curve, competing-risk regression model, Cox proportional hazards regression model, and proportional hazard assumption were used for statistical analyses. Results We identified 4,729 patients, including 1,062 patients were received postmastectomy radiotherapy (PMRT). Stage change occurred in 88.2% of the patients, of which 84.4% were downstaged and 3.7% were upstaged. Patients with higher pathological prognostic stages were independently predicted to receive PMRT. The 5-year breast cancer-specific survival (BCSS) was 97.5, 93.7, 90.1, 86.0, and 73.5% in disease stages IA, IB, IIA, IIB, and IIIA, respectively, according to the 8 th edition criteria (P < 0.001). The AJCC 8 th edition demonstrated moderate discriminative ability, and it had a significantly better ability to predict the BCSS than the AJCC 7 th edition criteria (P < 0.001). The multivariate prognostic analysis showed that the new pathological prognostic staging was an independent prognostic factor affecting the BCSS. The BCSS worsened with an increase in the stage. The PMRT did not affect the BCSS regardless of the pathological prognostic stage. Similar trends were found using the competing-risks regression model. Conclusions The 8 th AJCC breast cancer pathological prognostic staging system downstaged 84.4% of patients with T1-2N1micM0 disease and the survival outcome prediction with this staging system was more accurate than the AJCC 7 th edition system. Our study does not support using the prognostic stage as a guideline to escalate of PMRT.

oncology
Evaluation of the prognostic stage in the 8th edition of the American Joint Committee on Cancer in locally advanced breast cancer: An analysis based on SEER 18 database.

Maoli Wang,Hongliang Chen,Kejin Wu,Ang Ding,Mingdi Zhang,Peng Zhang

DOI: https://doi.org/10.1016/j.breast.2017.10.011

IF: 4.254

2018-01-01

The Breast

Abstract:•The new “prognostic stage” in the 8th edition of AJCC incorporated important biologic factors and TNM stage into one system.•The prognostic stage reassigned 74% locally advanced breast cancer patients.•According to the prognostic stage 60.4% cases in grade III and 68.3% cases in TNBC were upstaged while 57.1% cases with ER/PR dual positivity were down staged.•The prognostic stage was an independent prognostic factor of LABC.•Among each TNM stage, there were statistically significant survival differences among stage changes.

Surgical management of duodenal ulcer.

Validation of the pathological prognostic staging system proposed in the revised eighth edition of the AJCC staging manual in different molecular subtypes of breast cancer

A prospective observational study on the accuracy of patient self‐testing of urine at an antenatal clinic

Prognostic Stage Groups Established by AJCC Staging System 8th Edition Does Not Significantly Improve Discrimination over Classic TNM Staging in Early Stage Breast Cancer Treated with Breast Conservative Therapy

Validation of the Prognostic Significance of the Prognostic Stage Group According to the Eighth Edition of American Cancer Joint Committee on Cancer Staging System in Triple-Negative Breast Cancer: An Analysis From Surveillance, Epidemiology, and End Results 18 Database

Metal chelators coupled with nanoparticles as potential therapeutic agents for Alzheimer's disease.

Comparison of the 7th and 8th edition of American Joint Committee on Cancer (AJCC) staging systems for breast cancer patients: a Surveillance, Epidemiology and End Results (SEER) Analysis.

Validation of the American Joint Committee on Cancer (AJCC) 8th edition stage system for gastric cancer patients: a population-based analysis

Organochlorine pesticides associated with ocular, nasal, or otic infection in the eastern box turtle (Terrapene carolina carolina).

Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual

Pharmacokinetics of an antiallergic agent, 1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-1H-1, 4-diazepin-1-yl)-1H-benzimidazole difumarate (KG-2413) after oral administration: interspecies differences in rats, guinea pigs and dogs.

Validation of the Postneoadjuvant Therapy Pathological Stage of the American Joint Committee on Cancer (AJCC) 8th Edition for Predicting Outcomes of Esophageal Squamous Cell Carcinoma (ESCC) Patients Receiving Neoadjuvant Chemoradiotherapy (CRT) Followed by Esophagectomy.

The Effect of the New Eighth Edition Breast Cancer Staging System on 100 Consecutive Patients

Best-Worst Scaling: A simple method to determine drinks and wine style preferences

クロラムフェニコール, チアムフェニコール及びペニシリンによる老年者急性骨髄機能不全に関する血液学的検討, とくに末梢血液像および肝機能について

The Predictive Value of the Prognostic Staging System in the 8th Edition of the American Joint Committee on Cancer for Triple-Negative Breast Cancer: a SEER Population-Based Analysis

A Retrospective Survival Analysis of Anatomic and Prognostic Stage Group Based on the American Joint Committee on Cancer 8th Edition Cancer Staging Manual in Luminal B Human Epidermal Growth Factor Receptor 2-negative Breast Cancer.

The Prognostic Value of the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging System in HER2-Enriched Subtype Breast Cancer, a Retrospective Analysis.

Abstract PO5-27-01: Comparison between the 7th and the 8th edition of TNM Staging System of American joint committee on Cancer(AJCC) for Breast Cancer Patients, diagnosed and treated at King Abdulaziz Medical City

Prognostic and Predictive Value of the American Joint Committee on Cancer Pathological Prognostic Staging System in Nodal Micrometastatic Breast Cancer

Evaluation of the prognostic stage in the 8th edition of the American Joint Committee on Cancer in locally advanced breast cancer: An analysis based on SEER 18 database.